Suppr超能文献

奖励饮酒与纳曲酮治疗对青年重度饮酒者的反应。

Reward drinking and naltrexone treatment response among young adult heavy drinkers.

机构信息

Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.

Department of Psychology, University of New Mexico, Albuquerque, NM, USA.

出版信息

Addiction. 2021 Sep;116(9):2360-2371. doi: 10.1111/add.15453. Epub 2021 Mar 18.

Abstract

AIMS

Theory-driven, exploratory study to: (i) identify a reward drinking phenotype in young adults; (ii) evaluate this phenotype as a predictor of naltrexone response; and (iii) examine mechanisms of naltrexone in reward drinkers.

DESIGN

Secondary analysis of a randomized controlled trial.

SETTING

USA.

PARTICIPANTS

A total of 128 young adult (ages 18-25) heavy drinkers.

INTERVENTIONS

Naltrexone versus placebo.

MEASUREMENTS

Daily surveys assessed affect, urge, drinking, and context. The Drinking Motives Questionnaire was used to identify phenotypes based on reward (enhancement motives) and relief (coping motives) drinking.

FINDINGS

We identified three profiles: "Low reward/Low relief" (14.1%; low enhancement/low coping motives); "Reward drinkers" (62.2%; high enhancement/low coping motives); and "High reward/High relief" (22.7%; high enhancement/high coping motives). Among reward drinkers (versus low profile), naltrexone significantly reduced percent days drinking to intoxication (blood alcohol concentration [BAC] ≥0.08) (PDI) (d = 0.56; 95% CI [0.17, 0.96]) and percent high intensity drinking days (PHID) (8/10 drinks for women/men) (d = 0.32; 95% CI [0.01, 0.68]). Among the high reward/high relief profile drinkers (versus low profile), naltrexone reduced PHID (d = 0.69; 95% CI [0.02, 1.50]). Using profile-informed cutoffs and observed scores (for clinical applicability): (i) among cutoff-derived reward drinkers, we found a medium-to-large (d = 0.66; 95% CI [0.24, 1.16]) and small effect (d = 0.28; 95% CI [0.04, 0.72]) of naltrexone in reducing PDI and PHID, respectively; and (ii) among the cutoff-derived high reward/high relief subgroup, we found a medium-to-large effect (d = 0.63; 95% CI [0.05, 1.1]) of naltrexone in reducing PHID. Among reward drinkers (not other profiles), naltrexone reduced drinking on days a drinking event occurred by weakening the within-day association between positive affect and urges (P < 0.05).

CONCLUSIONS

Naltrexone has pronounced effects in reducing risky drinking among young adult reward drinkers (high reward/low relief) by reducing urges on days when individuals have higher positive affect and are exposed to a drinking event. Naltrexone also appears to reduce risky drinking among young adult high reward/high relief drinkers, but not via the same mechanism.

摘要

目的

一项基于理论的探索性研究旨在:(i)确定年轻人中的奖励性饮酒表型;(ii)评估该表型作为纳曲酮反应的预测因子;(iii)研究纳曲酮在奖励性饮酒者中的作用机制。

设计

随机对照试验的二次分析。

地点

美国。

参与者

共 128 名年轻成人(18-25 岁)重度饮酒者。

干预措施

纳曲酮与安慰剂。

测量

每日调查评估了情绪、冲动、饮酒和环境。使用饮酒动机问卷根据奖励(增强动机)和缓解(应对动机)饮酒来确定表型。

结果

我们确定了三种表型:“低奖励/低缓解”(14.1%;低增强/低应对动机);“奖励饮酒者”(62.2%;高增强/低应对动机);“高奖励/高缓解”(22.7%;高增强/高应对动机)。在奖励饮酒者中(与低表型相比),纳曲酮显著降低了醉酒日(血液酒精浓度[BAC]≥0.08)(PDI)(d=0.56;95%置信区间[0.17,0.96])和高强度饮酒日(PHID)(女性/男性 8/10 杯酒)(d=0.32;95%置信区间[0.01,0.68])。在高奖励/高缓解表型饮酒者中(与低表型相比),纳曲酮降低了 PHID(d=0.69;95%置信区间[0.02,1.50])。使用基于表型的截止值和观察到的分数(适用于临床应用):(i)在截止值衍生的奖励饮酒者中,我们发现纳曲酮对 PDI 和 PHID 的降低具有中到大(d=0.66;95%置信区间[0.24,1.16])和小(d=0.28;95%置信区间[0.04,0.72])的效应;(ii)在截止值衍生的高奖励/高缓解亚组中,我们发现纳曲酮对 PHID 的降低具有中到大(d=0.63;95%置信区间[0.05,1.1])的效应。在奖励饮酒者中(非其他表型),纳曲酮通过削弱个体在积极情绪和冲动较高的日子之间的日内关联,降低了饮酒日的饮酒量(P<0.05)。

结论

纳曲酮在减少年轻成人奖励性饮酒者(高奖励/低缓解)的高危饮酒方面具有显著效果,通过降低个体在积极情绪和暴露于饮酒事件时的冲动来实现。纳曲酮似乎也降低了年轻成人高奖励/高缓解饮酒者的高危饮酒,但不是通过相同的机制。

相似文献

引用本文的文献

本文引用的文献

1
The future of translational research on alcohol use disorder.酒精使用障碍转化研究的未来。
Addict Biol. 2021 Mar;26(2):e12903. doi: 10.1111/adb.12903. Epub 2020 Apr 14.
2
Advances in the science and treatment of alcohol use disorder.酒精使用障碍的科学和治疗进展。
Sci Adv. 2019 Sep 25;5(9):eaax4043. doi: 10.1126/sciadv.aax4043. eCollection 2019 Sep.
9
Vulnerability for Alcohol Use Disorder and Rate of Alcohol Consumption.酒精使用障碍的易感性与酒精消费率
Am J Psychiatry. 2017 Nov 1;174(11):1094-1101. doi: 10.1176/appi.ajp.2017.16101180. Epub 2017 Aug 4.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验